Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2528648 | 0.85 | SLC6A4 (0.46) | SLC6A4NOS2CTSSCTSKGPR119 | |
| SCHEMBL2528904 | 0.83 | SLC6A4 (0.46) | SLC6A4NOS2GPR119MBOAT4GAA | |
| SCHEMBL2529134 | 0.82 | SLC6A4 (0.45) | SLC6A4NOS2GPR119MBOAT4GAA | |
| SCHEMBL2531403 | 0.82 | SLC6A4 (0.45) | SLC6A4NOS2GPR119GAAL3MBTL1 | |
| SCHEMBL2530724 | 0.82 | SLC6A4 (0.45) | SLC6A4NOS2GPR119MBOAT4GAA | |
| SCHEMBL2528769 | 0.81 | GAA (0.50) | SLC6A4NOS2CTSSGPR119MBOAT4 | |
| SCHEMBL2532315 | 0.81 | SLC6A4 (0.49) | SLC6A4NOS2GPR119AR | |
| SCHEMBL2526298 | 0.81 | SLC6A4 (0.44) | SLC6A4NOS2GPR119GAAL3MBTL1 | |
| SCHEMBL2526190 | 0.80 | SLC6A4 (0.43) | SLC6A4NOS2GPR119MBOAT4GAA | |
| SCHEMBL25382669 | 0.79 | NOS1 (0.41) | NOS2EGLN2MBOAT4CHEK1CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | SERENTRIX, LLC | 2019-03-19 | — | — | US | disclosed |
| EP-2552888-B1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | SERENTRIX LLC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | SERENTRIX LLC (US) | 2016-10-06 | — | — | US | disclosed |
| US-9216975-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | Serentrix, LLC. (US) | 2015-12-22 | — | — | US | disclosed |
| CN-102858742-B | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2015-05-27 | — | — | CN | disclosed |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | PHARMESTE S.R.L. (IT) | 2013-03-28 | — | — | US | disclosed |
| EP-2552888-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | Pharmeste S.r.l. (IT) | 2013-02-06 | — | — | EP | disclosed |
| CN-102858742-A | Trpv1 vanilloid receptor antagonists with a bicyclic portion | PHARMESTE SRL | 2013-01-02 | — | — | CN | disclosed |
| WO-2011120604-A1 | \"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION\ | PHARMESTE S.R.L. (IT) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152252-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | SLC6A4 1353/4885NOS2 3639/4885EGLN2 1861/4885 |
| US-10233177-B2 | TRPV1 vanilloid receptor antagonists with a bicyclic portion | TRPV1, TRPV5, TRPV3 | SLC6A4 1353/4885NOS2 3639/4885EGLN2 1861/4885 |
| US-20160289199-A1 | TRPV1 Vanilloid Receptor Antagonists With A Bicyclic Portion | TRPV1, TRPV5, TRPV3 | SLC6A4 1353/4885NOS2 3639/4885EGLN2 1861/4885 |
| US-20130079339-A1 | TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION | TRPV1, TRPV5, TRPV3 | SLC6A4 1353/4885NOS2 3639/4885EGLN2 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.